Agreement - July 2, 2015
Targovax, Oncos Strike Deal
Norwegian Targovax has entered an agreement with the shareholders of Finnish clinical-stage biotechnology company Oncos Therapeutics to acquire the shares of Oncos with settlement in Targovax shares. After the transaction, the shareholders of Oncos will own 50 per cent of Targovax. The new company already has received indications of interest from leading institutional investors, including a 26 […]
In a new job - June 11, 2014
New CMO for Oncos Therapeutics
Finnish Oncos Therapeutics Ltd has appointed Dr Magnus Jaderberg, M.D, Ph.D, as Chief Medical Officer. Dr Jaderberg joined Oncos Therapeutics on June 1, 2014. “We are very happy to announce the recruitment of Magnus to our team. He will bring strategic expertise and knowledge to our prioritized research and clinical development of novel cancer immune therapies”, […]
Clinical Trials - May 9, 2014
Oncos Therapeutics presents achievement in cancer immunotherapy
The clinical stage biotechnology company has presented data on its lead compound, ONCOS-102. The data, presented in two separate podium presentations on May 7th and 8th at the Annual Meeting of the Association for Cancer Immunotherapy (CIMT) in Mainz, Germany, demonstrated that local administration of ONCOS-102 is able to induce a systemic, tumor-specific immune response in late-stage cancer […]
